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CONCLUSIONS: Resource utilization and costs associated with migraine increased
with greater headache frequency. Treatments that reduce headache frequency
have the potential to have a positive economic impact by reducing costs associated
with migraine care.
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OBJECTIVES: To conduct a pilot study examining the validity and reliability of a
paper-based standard gamble (PSG) instrument and to administer the validated
PSG among persons with hemophilia B enrolled in the Hemophilia Utilization
Group Study (HUGS-Vb). METHODS: Fifteen pharmacy students were enrolled in
this pilot. We presented a hypothetical scenario describing a patient with severe
hemophilia to each participant, followed by three tests: (1)Standard Gamble (SG)
using the probability wheel, (2)PSG and (3)Visual Analog Scale (VAS), each admin-
istered in random order. PSG was re-administered after two weeks to assess test-
retest reliability. The validated PSGwas subsequently administered to participants
enrolled in HUGS-Vb, a prospective, multicenter study collecting utilization and
other data associated with hemophilia B in the United States. Participants or their
parent(s) completed a demographic questionnaire, the PSG and the EQ-5D. A PSG
scenario based on actual demographic and clinical characteristics was created for
each participant. Paired t-test, Spearman rank correlation coefficient (rho) and
intra-class correlation coefficient (ICC) were used to assess the convergent validity
and reliability of the instrument. RESULTS:Mean SG, PSG and VAS in the pilot were
0.790.15, 0.820.14 and 66.823.0, respectively. The mean difference between
PSG and SG did not differ significantly from 0 (p0.124). PSG was significantly
correlated with SG (rho0.769, p0.0008) and VAS (rho0.534, p0.0405). PSG re-
test score was 0.790.13 and test-retest ICC was 0.85 (95% CI: 0.63-0.94; p0.0001).
Of 71 HUGS-Vb participants, 32 (45%) were adults; 38 (54%) had severe hemophilia.
Mean agewas 21.8 years (range 2-61). Mean PSG andVAS scoreswere 0.910.15 and
84.414.6 respectively, with weak correlation between the two (rho0.242,
p0.0452) in the full sample. Adult PSG and EQ-5D scores were 0.870.18 and
0.850.16 respectively, with correlation rho0.348 (p0.0506). CONCLUSIONS: A
paper-based standard gamble instrument may be a valid, reliable alternative to SG
for measuring health utility in hemophilia patients.
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OBJECTIVES: To map the Insomnia Severity Index (ISI) to the EQ-5D utilities.
METHODS: A cross-sectional, online survey was conducted among adult US resi-
dents with self-reported sleep problems. Respondents provided demographic, co-
morbidity, previous-night sleep-related information and, completed the EQ-5Dand
the ISI, a seven-item instrument measuring perceived insomnia severity. Each ISI
item is scored from 0-4 with minimum total score of 0 (no insomnia) and a maxi-
mum of 28 (most severe insomnia). Respondents can be classified into four ISI
categories (0-7: no clinically significant insomnia; 8-14 subthreshold insomnia; 15-
21: moderate insomnia; 22-28: severe insomnia). Generalized linear models were
used to map the seven ISI items (Model 1), the ISI summary scores (Model 2), and
the four ISI clinical categories (Model 3) onto EQ-5D utilities. Predictions were esti-
mated using 50/50 split sample validation. Model fits were assessed using mean
squared error (MSE) and distributional quality of predicted values. RESULTS: Re-
spondents (n2,842) were predominantly middle-aged, female, Caucasian, with
1 comorbidity. Mean sleep duration was 7.8 (1.9) hours, mean ISI score was 14.1
(4.8). Mean predicted utilities were (0.7650.08) across all models, overlapping
with observed utilities (0.7650.18). Using Model 1, predicted utilities increased
linearly with improving ISI (0.493 if ISI28; 1.00 if ISI0, p0.01). In Model 2, each
unit decrease in ISI summary was associated with a 0.022 (p0.001) increase in
utility. Predicted utilities were 0.868, 0.809, 0.722 and 0.579 for no clinical, sub-
threshold, moderate and severe insomnia, respectively (Model 3). The overall MSEs
betweenpredictedandobservedutilitiesweregood inallmodels (Model I: 0.025,Model
II & III: 0.026), especiallywhenpredicting utilities0.40 (MSEs: 0.016-0.056).MSEswere
higher when predicting lower utilities (MSEs: 0.138-0.156). CONCLUSIONS: Linear re-
lationshipswere found between EQ-5Dutilities and the ISI. These relationships can
be used to estimate the impact of insomnia-associated treatment effects on utili-
ties.
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OBJECTIVES: To create and implement a secure web-based research program
that collects and tracks validated patient-reported outcomes (PROs) for multiple
sclerosis (MS) patients and their healthcare providers (HCP).METHODS: The My
MS Health program can be accessed through a HIPAA secure website, www.
mymshealth.org. A pilot study to evaluate the My MS Health program has been
IRB-approved. Assessment of inclusion/exclusion criteria, enrollment, and in-
formed consent with an electronic signature occurs through this secure web-
site. Enrolled patients are prompted to complete a series of nine validated PRO
surveys that measure MS specific symptom status, functional status, and qual-
ity-of-life, and results are immediately available. Patients may elect to give their
HCP access to their real-time PRO results electronically. Aggregate data analysis
can also be performed on the collected PRO data. RESULTS: In this ongoing study,
927 patients were enrolled and 122 were eligible to participate in the program
evaluation survey at three months. Scores were measured on 5-point Likert scales
with a range of low agreement (1) to high agreement (5) and scores greater than or
equal to 3 signify agreement. Overall, 93% felt the amount of time it took to answer
the surveys was just right, and 91% felt the website was easy to use (4.51.05). In
addition, 92% reported they would likely continue participating in the program
(4.081.11) and 78% reported they would likely recommendMyMS Health to others
(3.851.48). CONCLUSIONS: Preliminary results indicate My MS Health is an effi-
cient and user friendly technology platform that patients will continue to use.
Future evaluations will assess the impact of using the program on patient and HCP
communication.
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OBJECTIVES: To assess the relationship between internal locus of control (ILOC)
and treatment satisfaction in MS patients after 1 year of natalizumab treatment.
METHODS: MS patients completed the Treatment Satisfaction Questionnaire for
Medication (TSQM) prior to natalizumab initiation (BL) and after the 12th natali-
zumab infusion. Effectiveness, Convenience and Global Satisfaction subscale
scores range from 0 to 100; higher scores indicate higher satisfaction. ILOC was
assessed at BL and after the 12th infusion using the ILOC subscale of the Multidi-
mensional Health Locus of Control questionnaire. Subscale scores range from 6 to
36; higher scores indicate greater ILOC. Correlation analysis and regressionmodels
evaluated the relationship between ILOC and satisfaction with natalizumab after
12 infusions, controlling for BL patient characteristics. RESULTS: A total of 333
patients (mean age 46.810.4 years and median of 9 years since MS diagnosis)
completed all assessments. BL and 12th ILOCwas correlatedwith BL and 12th Global
Satisfaction (r0.13, p0.0247 and r0.27, p0.0001, respectively) and Effective-
ness (r0.23, p0.0001 and r0.29, p0.0001, respectively); 12th ILOC was corre-
lated with 12th convenience (r0.12, p0.0373). Regression model results showed
that, after controlling for covariates, higher ILOC predicted greater global satisfac-
tion (p0.003), effectiveness (p0.001) and convenience (p0.017) with natali-
zumab after 12 infusions. CONCLUSIONS: Patients with MS with stronger internal
beliefs about having control over their own health have higher satisfaction with
natalizumab treatment after 12 infusions. Interventions supporting and reinforc-
ing patients’ health beliefs may have a positive impact on overall treatment satis-
faction resulting in improved treatment adherence.
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OBJECTIVES: The Short Parkinson’s Evaluation Scale/Scales for Outcomes in Par-
kinson’s disease (SPES/SCOPA) was developed as a reliable and valid scale to eval-
uate motor impairment in Parkinson’s disease (PD) patients and can be completed
in less time than the gold standard Unified Parkinson’s Disease Rating Scale (UP-
DRS). This study aimed to further investigate the reliability and validity of the
SPES/SCOPA motor clinical examination, as relatively little research in the US has
done so.METHODS: The BRAVURA study was designed to investigate order effects
associated with the UPDRS motor examination at 2 centers in the US. Patients,
stratified by center and previous Hoehn and Yahr (H&Y) stage, were randomly
assigned to 1 of 2 UPDRS item sequences. All scale evaluations occurred during a
single clinic visit. In addition to the 8-item SPES/SCOPAmotor clinical examination
and the 14-itemUPDRSmotor examination, scales included current H&Y stage and
patient- and physician-rated Schwab and England Activities of Daily Living (ADL).
Datawere analyzed using Cronbach’s alpha and Spearman’s correlation. RESULTS:
Complete data were available for 112 patients (mean time from diagnosis  6.4
years). Relationships among the scales were comparable across the 2 experimental
groups, thus data were pooled for these analyses; SPES/SCOPA mean score  9.5
(SD  5.2). The SPES/SCOPA demonstrated good internal reliability (alpha  0.79).
Construct validity was supported with the SPES/SCOPA correlating 0.76 with the
UPDRS. Furthermore, the SPES/SCOPA correlated 0.47 with current H&Y stage and
0.39, 0.45 with patient- and physician-rated ADL, respectively. CONCLUSIONS:
In this US sample of PD patients with varied disease severity, the SPES/SCOPA
exhibited good psychometrics, including evidence of construct validity with the
current standard of motor impairment measurement. The SPES/SCOPA also had
good internal consistency and correlated with 3 broad evaluations of disease dis-
ability in a similar fashion to the UPDRS.
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OBJECTIVES:Multiple sclerosis (MS) and Alzheimer’s Disease (AD) are chronic and
progressive diseases that have the potential to impose a significant burden on both
caregivers and the immediate families of patients. Extensive literature has docu-
mented MS and AD caregiver burden on physical and mental health; but there are
no direct comparisons of MS and AD caregivers. This study examined the extent of
MS caregiver burden compared to non-caregivers and caregivers of AD patients.
METHODS:Datawere obtained from the 2009National Health andWellness Survey
administered online to a US representative adult sample (N75,000). Respondents
reported health status, quality of life, work productivity, healthcare utilization and
caregiver status. Multivariable regressions, adjusting for key characteristics (e.g.,
age, gender, marital status, depression), were conducted to explore differences
between MS caregivers (n215) vs. non-caregivers (n69,224), as well as MS care-
givers vs. AD caregivers (n1,341). Rate ratios (RR) and regression weights (b) are
reported. RESULTS: Compared to non-caregivers, MS caregivers had significantly
greater activity impairment (RR1.41; p0.01) and poorer mental (b1.44;
p0.015), physical (b1.96; p0.002), and health utility scores (b0.03;
p0.002), along with more traditional healthcare provider visits (RR1.46;
p0.0001), ER visits (RR2.16; p0.0001), and hospitalizations (RR2.20; p0.001)
after covariate adjustment. Compared to AD caregivers, MS caregivers had greater
activity impairment (RR1.29; p0.044) and more ER visits (RR1.60; p0.017) and
hospitalizations (RR1.92; p0.008) after covariate adjustment. Work productivity
differences were not observed in comparison with either group, potentially due to
the small number of employed MS caregivers in the sample (n126).
CONCLUSIONS:MS caregivers had significantly more burden compared with non-
caregivers. In addition, the results suggest an even greater burden to these indi-
viduals than observed among AD caregivers. The results of this analysis of a na-
tional survey reveal the hidden toll of those providing care for MS patients and
highlights the need to recognize their burden so that appropriate measures can be
implemented.
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OBJECTIVES: To evaluate changes in patient reported fatigue and cognitive func-
tion after one year of natalizumab treatment in multiple sclerosis (MS) patients.
METHODS: The study population consists of MS patients initiating natalizumab
treatment who agreed to participate in a 12 month longitudinal study. Patients
reported experiences with natalizumab using validated patient-reported outcome
(PRO) measures prior to natalizumab treatment initiation (BL) and after 3rd, 6th and
12th infusion. The current analysis reports change in fatigue and cognition from
baseline through the 12th natalizumab infusion. Fatigue was measured by the
5-question Modified Fatigue Impact Scale-5 (MFIS-5, score range 0-20) with lower
scores indicating lower impact of fatigue on physical, cognitive, and psychosocial
functioning; cognitive functionwasmeasured by the 6-questionMedical Outcomes
Study Cognitive Functioning Scale (MOS-Cog Scale, score range 6-36) with higher
scores indicating better reasoning skills, memory, concentration, ability to start
several actions at one time and ability to react to what is said or done. Regression
analysiswas used to control for BL covariates such as age, years sinceMSdiagnosis,
number of natalizumab infusions received, disability and functional status, num-
ber of MS drugs used prior to natalizumab and comorbidity burden. RESULTS:Data
for 324 patients who completed the BL through 12th infusion assessments are re-
ported. Themean age was 46.5 (SD10.4) and themajority of patients were female
(77.8%). The mean number of years since MS diagnosis was 10.16 (SD8.23). On
average, MFIS scores decreased significantly (BL 12.362.18; 12th infusion score
11.162.18, p0.001) and MOS-Cog scores increased significantly over time (BL
25.121.51; 12th infusion score 26.191.97, p0.001) after controlling for
covariates. CONCLUSIONS: MS patients reported improvements in fatigue and
overall cognitive function after one year of natalizumab treatment.
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OBJECTIVES: There is abundant evidence that individuals with Multiple Sclerosis
(MS) have compromised quality of life (QOL) and work productivity, and increased
healthcare resource use compared to individuals without MS. The possible associ-
ation between subjects’ self-reported severity of disease and these variables in an
MSpopulation has only recently been explored. Patient perceptions of disease have
been increasingly recognized as an important factor in healthcare resource use.
The objective of this study was to analyze the association between perceived se-
verity of disease (mild, moderate, or severe) and symptoms, quality of life, work
productivity, and healthcare resource use in individuals with MS.METHODS: Data
from respondents reporting anMS diagnosis were obtained from the 2009 National
Health andWellness Survey (NHWS), an Internet-based annual study of the health-
care attitudes and behaviors of a US representative adult sample. The survey in-
cluded questions about demographics, disease severity, symptoms, quality of life,
work productivity, and healthcare resource use. RESULTS: In the 2009 NHWS
study, 536 reported an MS diagnosis. MS respondents characterized the severity of
their disease as follows: mild (n206; 38.4%), moderate (n268; 50%); and severe
(n62; 11.6%). There were no differences in the number of years since diagnosis
among the groups but there were significantly more men in the severe group. As
perceived severity increased among MS patients (mild, moderate, severe), symp-
tom severity generally increased, QOL decreased (SF-12 Physical Component
Score), percent with full-time employment decreased, loss of work productivity
and presenteeism increased among those reporting employment and healthcare
resource use increased (ER visits and hospitalizations). CONCLUSIONS: Generally,
those withmore severe illness reported greater impairment. However, for many of
the variables examined, more significant differences were found between patients
who perceive their disease severity as mild and moderate than those patients
reporting moderate and severe disease severity.
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OBJECTIVES: This study evaluated and examined the relationship between parent-
ing stress in caring for children diagnosed with a neuro-developmental disorder.
METHODS: A cross-sectional study was conducted by using a self-administered
questionnaire distributed through schools that provide services for children with
developmental disorder. Parents with children aged 3-18 years and diagnosedwith
a neuro-developmental disorder were requested to complete the survey. Previ-
ously validated scales, the Parenting Stress Index (PSI) and the Columbia Impair-
ment Scale (CIS) were used along with scales to measure parent and child’s char-
acteristics. Data was coded and analyzed using SAS v9.2 by performing descriptive
and regression analyses. RESULTS: A total of 150 surveys were received from 4
schools net response rate (26.5%). Themean parent’s age was 45.7(6.4) years with
mothers being higher portion of respondents (84%) and most (90%) were married.
Mean PSI reported was 96.9(23.9) and clinically significant (85). Higher PSI was
attributed to the difficult child (DC) subscale (35.610.4) followed by parental dis-
tress (PD) subscale (31.89.3) and the parent-child dysfunctional interactions
(PCDI) subscale (30.28.5). Reliability coefficients for the PSI was high (0.91), includ-
ing the subscales (DC0.85, PD0.87, and PCDI0.8). Mean summary score for CIS
was 19.1(10.7) with a reliability coefficient of 0.9. A multiple regression analysis
indicated a positive relationship of PSI with developmental impairment (CIS,
1.43 p0.0001) after controlling for child’s characteristics (age, gender, diagno-
sis, number of children, child with similar diagnosis, relationship of parent) and
parent’s characteristics (age, race, education, employment status, income and ex-
isting disorder). CONCLUSIONS: Children with severe developmental impairment
may lead to greater stress for parents. Untreated stress can cause diseases, such as
heart diseases and depression. Interventions controlling stress is the key to im-
proving parents’ quality of life for those that care for children with neuro-develop-
mental disorders.
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OBJECTIVES: The impact of Parkinson’s disease (PD) on the quality of life of both
patients and their carers has not been well documented. This study describes the
health status of both PD patients and caregivers asmeasured on a genericmeasure
of health status (SF-12), and then explores to what extent patient self-reported
health, as measured on the disease-specific Parkinson’s Disease Questionnaire
(PDQ-39), is associated with carer strain and self-reported quality of life.
METHODS:Apostal surveywas carried out of both patients and caregivers through
local branches of Parkinson’s UK. Questionnaire packs were sent to those on the
database with a diagnosis of PD. Patients were asked to give the carer question-
naire to theirmain caregiver, if they had one. RESULTS: Results suggest that PD has
substantial adverse effects on both the physical (measured by the Physical Com-
ponent Summary, PCS) andmental well-being of patients (measured by theMental
Component Summary, MCS) when compared with population norms. Most strik-
ingly PD patients PCS scores fall within the lowest 10% of results, compared with a
wider general population sample. While carer physical health was not found to be
substantially different from that of the general population, emotional health was
severely compromised with a MCS score that places them in the lowest 22% of the
population. Regression analysis suggests that the major predictors of carer strain
are the PDQ scales of mobility and social support. Carer strain was found to be
closely associated with carer mental health. CONCLUSIONS: PD impacts on the
well being of both patients and caregivers; the data provide evidence that the
health status of the patient, in particular their physical health, has a significant
impact on the well-being of their caregivers.
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OBJECTIVES: To describe key characteristics of members of the online, USA-based
PatientsLikeMe® Epilepsy Community, by comparison with a widely-used USA
claims database, PharMetrics®, and to assess the impact of epilepsy on patients’
lives using patient-reported data, collected through PatientsLikeMe®. METHODS:
The PatientsLikeMe® Epilepsy Community allows patients with epilepsy to record
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